Pfizer Inc. (PFE)

Novo Nordisk changes tack with bold raid on Pfizer obesity deal

Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish drugmaker as it seeks to regain ground in the weight-loss drug market under a new CEO and board.

Metsera the US obesity biotech at centre of Novo, Pfizer bidding war

Metsera has become the obesity drug market's hottest ticket.

10 Ideal 'Safer' Dividend Buys From 38 Of 68 October Graham Value All-Stars (GVAS)

The article analyzes the top large-cap value (GASV) stocks using YCharts' Value Score and Ben Graham Formula to identify fair-priced, high-yield dividend opportunities. Ten of eighteen 'safer' lowest-priced GASV stocks, including ET, MPLX, YRD, VZ, BMY, TFC, T, SU, MFC, and BBVA, are considered buyable in October. Analyst projections suggest the top ten GASV stocks could deliver average net gains of 38.01% by October 2026, with Lexinfintech Holdings leading potential returns.

Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'

On Thursday, Metsera Inc. (NASDAQ:MTSR) received an unsolicited acquisition proposal from Novo Nordisk A/S (NYSE:NVO).

What Analyst Projections for Key Metrics Reveal About Pfizer (PFE) Q3 Earnings

Evaluate the expected performance of Pfizer (PFE) for the quarter ended September 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

5 High-Yield Stocks to Anchor Your Portfolio for Half a Decade

There's no better way to generate passive income than dividend stocks. If a stock has a dividend yield higher than the common benchmark, such as the S&P 500, it could be a worthwhile investment.

3 Stocks Under $30: Where to Put $1,000 to Work Today

Earnings Preview: Pfizer (PFE) Q3 Earnings Expected to Decline

Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Pfizer's Headwinds May Already Be In The Price

Pfizer faces significant revenue headwinds from patent expiries, COVID product declines, and generic competition, but these risks are largely priced in. PFE's valuation is historically low at ~8x earnings, reflecting aggressive patent cliff assumptions and conservative growth projections for existing products. Pipeline and acquisition success, especially in obesity/diabetes, could drive capital appreciation, with even partial wins supporting a rerating toward historical multiples.

PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now?

Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast a dominant position in the lucrative oncology space.

Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

2 Safer High-Yield Stocks That Can Pay Boomers for Life

Baby Boomers should be looking to play things a bit more cautiously as stock valuations begin to climb across the board.

My Top 3 Pharma Stocks

Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and offer dividend yields even higher than IT, as well as oil and gas stocks. In this article, I reveal my top 3 Big Pharma players.

Pfizer's Q3 Non-Oncology Performance: Here's What to Expect

Pfizer's Q3 results are set to reveal mixed trends across non-oncology drugs, with strong Eliquis and Paxlovid sales offset by weakness in Abrysvo and Xeljanz.

Novo Vs. Lilly Vs. Pfizer: Who Wins If Trump Slashes The Price Of Weight Loss Drugs?

President Donald Trump just dropped a political bomb into one of Wall Street's hottest trades. His promise to cut the cost of Novo Nordisk A/S (NYSE:NVO) blockbuster drug Ozempic from around $1,300 to $150 isn't just about affordability—it's about shaking the foundations of the GLP-1 gold rush that's reshaped healthcare valuations from Eli Lilly And Co (NYSE:LLY) to Pfizer Inc (NYSE:PFE).

What's Behind The Slump In Pfizer Stock?

Pfizer stock (NYSE: PFE) is currently in a significant slump, marking its ninth consecutive day of decline and losing a total of −11% of its value over that period. This sustained sell-off has wiped out approximately $18 billion in market capitalization, leaving its current value at around $138 billion.

CEOs of Wells Fargo and Pfizer caution the U.S. could lose its edge to China without innovation

Wells Fargo CEO Charlie Scharf said AI is boosting productivity but will likely reduce workforce size. Pfizer CEO Albert Bourla warned China is closing the biotech and pharmaceutical patent gap rapidly and said the U.S. needs to focus on innovation.

Pharma M&A Activity Picks Up Pace: What Does It Signal for 2026?

Big Pharma reignites dealmaking as Pfizer, Novo Nordisk and Roche target obesity and metabolic diseases in a high-stakes 2025 M&A surge.

Top Dividend Stocks Delivering Over 5% for True Financial Freedom

It is possible to achieve financial freedom through stock investing. If you pick the right companies, stay invested for the long term, and reinvest the dividends, you can build a solid portfolio for retirement.

3 Sizzling Ultra-High-Yield Stocks Under $50 With Upside Potential

Investors can have their higher yields and capital appreciation potential, too. But, of course, there are always added risks to consider, and when it comes to the hard-hit higher-yielders out there, the fundamentals and growth narrative have taken a turn for the worse.

Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Pfizer's Q3: The Catalyst For A Bullish Resurgence (Earnings Preview)

Pfizer's stock is poised for recovery, driven by recent corporate news and a three-year reprieve on drug-import tariffs from the Trump administration, strengthening the bullish case despite prior market reactions. Upcoming Q3 earnings on November 4, 2025, are expected to provide clarity on oncology progress and the impact of the Trump administration's tariff decision, potentially leading to meaningful earnings revisions. Pfizer's deal with TrumpRx, offering drug discounts and committing $70 billion in U.S. manufacturing/R&D, reduces regulatory uncertainty and should attract new investors as guidance is met.

Here's What to Expect From Pfizer's Oncology Drugs in Q3 Earnings

Pfizer's oncology strength, powered by Seagen's ADCs and key drugs like Xtandi and Lorbrena, is likely to be in focus ahead of Q3 earnings.

Life sciences sentiment rises as Pfizer deal eases tariff concerns

Sentiment towards life sciences tools and diagnostics firms in North America is turning positive after an agreement between the Trump Administration and Pfizer Inc (NYSE:PFE, ETR:PFE) has significantly eased the uncertainty around Most Favored Nation (MFN) tariffs on pharmaceuticals and related products, Citi analysts have highlighted. Under the deal announced late last month, Pfizer agreed to lower drug prices for Medicaid, sell discounted medicines directly to Americans, make significant investments in the US, and avoid tariffs for three years.

Trump's Drug Price Cuts: Boom or Bust for These 3 Pharma Giants

When investors hear that a company will lower prices on its products, their instinctive reaction is to expect a sequential decline in margins and profits, which is not entirely incorrect. However, sometimes these price decreases end up attracting new business, expanding market share, and more than making up for the lost ticket price in the top-line revenue.

My Top 5 Biotech Stocks Big Pharma Could Buy Next

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.

Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?

Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

3 Stocks Yielding 5% and More to Buy and Hold for the Next 5 Years

3 High-Yield Dividend Stocks to Buy in October

To investors, the stock market is considered one of if not the greatest ways to build wealth.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.